Alzheimer's Disease
NGP Technology
NGP Product
Patents and Publications

Alzheimer's Disease

Alzheimer’s Disease (AD) is a progressive brain disease that slowly destroys memory and thinking skills. It is the most common cause of dementia among older people, with symptoms often appearing by the age of 60. The effects are loss of cognitive function such as thinking, remembering and reasoning to the extent of interfering with a person’s daily life.

  • Amyloid plaques deposited in the brain are believed to precede the onset of dementia by many years. These plaques are seeded by the “bad amyloid” (Αβ42), and cause or contribute to the cognitive decline of AD patients.
  • Alzheimer’s Disease afflicts more than 5.3 million Americans (33 million worldwide) at an annual cost of 200 billion dollars.
  • New cases of Alzheimer’s Disease are on the rise, and it is projected that by 2020 nearly 6 million people in the US will be initially diagnosed with Alzheimer’s dementia.
  • Early preventative treatment is dependent on the diagnosis of amyloid plaque pathology before dementia.
  • Amyloid plaques are best detected by radiolabeled PET scans and may be prevented and removed by the right medicine.